Update on Dry Age-Related Macular Degeneration

Scheie Eye Institute, University of Pennsylvania
Tuesday, January 3, 2017
Macular degeneration scientist looking through a microscope

New treatments for the advanced form of dry age-related macular degeneration (AMD) are on the horizon. Learn about these new experimental drugs; novel mechanisms that are actively being studied regarding the development of macular degeneration; and helpful suggestions that might decrease your risk of progression to the late stage of this eye disease.

Patients often ask, "Do I have wet AMD?" In other words, are new blood vessels growing into the retina, causing harmful leakage of blood? If the answer is "yes," then this form of macular degeneration can now be treated by injection of medicines such as Lucentis, Eylea, or Avastin into the eye. But, if the answer is "no," and the patient has the dry form of AMD, what treatment options are then available? It all depends on whether the dry AMD is in the early or late stages.

Video: Dry Macular Degeneration

View Video

Early-Stage Dry AMD

Early dry AMD means the patient has drusen, little pebble-like deposits under the retina, and, in most cases, still has good vision. Late dry AMD, also called geographic atrophy, means that the photoreceptors (vision cells) have died in a specific region of the retina, and more are likely to die over the coming years, causing an expanding blind spot near the center of the visual field.

Fortunately, many patients with early AMD do not progress to late AMD. The risk of progression is determined by genetic factors, as well as diet, exercise, and smoking.

Decreasing Your Risk

It is very important to avoid or stop smoking, eat fatty fish like salmon, tuna, mackerel, or sardines twice a week, and eat lots of vegetables and some fruit.

Wearing sunglasses when outside may also be protective.

In addition, for patients with large or numerous drusen, vitamins designed according to the AREDS II trial decrease the risk of progression by 25%. If your ophthalmologist recommends taking them, be sure to look for “AREDS II formula” on the bottle in the drug store, as there are many different vitamins marketed for eye protection. One pill should be taken in the morning and one in the evening.

Further Resources on Reducing Risk of Macular Degeneration

Late-Stage Dry AMD

For patients with late dry AMD (geographic atrophy), there is no proven treatment to prevent or slow progression, but several new drugs are in advanced clinical trials.

Targeting the Immune System

The drug Lampalizumab targets a protein called complement factor D, which is part of the immune system. Both genetic and biochemical evidence indicate that the complement system is involved in AMD. In phase II trials, Lampalizumab decreased the rate of geographic atrophy expansion in a subset of patients with certain complement gene mutations. Lampalizumab is injected into the eye. While genetic testing for AMD is not currently helpful, results of the Lampalizumab trial may show that patients with certain gene mutations benefit from treatment. If so, this would be a reason for genetic testing.

Some other drugs in clinical trials for geographic atrophy include the complement inhibitor Zimura, which inhibits a different complement protein called complement factor 5. Like Lampalizumab, this treatment is injected into the eye.

Targeting Inflammation

There is also an oral drug called Oracea, the antibiotic doxycycline. It has anti-inflammatory activities that may be beneficial for patients with geographic atrophy.

Another orally administered pill just entering clinical trials is the antioxidant lipoic acid, and this study is funded in part by BrightFocus Foundation. This drug was able to protect mice against retinal degeneration in my lab, and is retina-protective in several other preclinical models.

Other Promising Avenues

Research on AMD continues to increase understanding of the disease and identify promising new drugs for testing in clinical trials. Several other mechanisms are actively being studied regarding the development of macular degeneration:

  • The inflammasome is a protein complex that can promote harmful inflammation and even retinal cell death.
  • Oxidative stress can be caused by bright light, antioxidant deficiency in a poor diet, and too much iron in the retina. Oxidative damage occurs when our bodies produce very reactive molecules that can adversely interact with other molecules inside of our cells. The resulting “inflammation” can contribute to a number of age-related diseases, including age-related macular degeneration.
  • A recent preliminary study showed that a statin drug, which inhibits cholesterol synthesis, could decrease the number of drusen in some patients.
  • Amyloid-beta, a protein that accumulates in the retinas of people that have AMD, and in the brains of Alzheimer’s patients, has the potential to cause retinal damage. A drug that removed amyloid-beta was protective in a mouse model of AMD.


Given the number of new important discoveries about the mechanisms of AMD, and the results of some promising early-stage clinical trials, it is likely that within the next few years we will have new treatments for AMD that reduce the risk of vision loss.

The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.

These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.

Some of the content may be adapted from other sources, which will be clearly identified within the article.

More Like This

  • Paitent with macular degeneration optimizing their glasses prescription

    Glasses and Macular Degeneration

    People with age-related macular degeneration (AMD) can have a wide range of visual impairment: some with early AMD have almost normal vision, while others with advanced AMD have lost most of their central vision. For many, the right glasses can be helpful.

    Monday, July 31, 2017

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Keep me imformed about: *
Please select at least one.
You must select at least one disease category.
Please enter your first name.
Please enter your last name.